Replies to post #159248 on Biotech Values

[pcrutch]

That's fine and dandy, but think too many got comfortable with this notion that Iclusig would just sweep up 1L and 2L, despite head-to-head data. Safety matters greatly to patients and community oncologists.

I do get the feeling Harvey is rushing it a bit. As biomaven said, they probably could use a little more work on dosing strategies if they want front-line and second-line.